An analysis of 3,180 terminated Phase 2 and Phase 3 trials shows late-stage termination rates doubling over a decade, with business and portfolio decisions overtaking scientific causes.
3,180 terminated Phase 2 and Phase 3 trials analyzed.
News
Selected research, company news, and perspectives.
A curated archive of our work, the evidence behind it, and the strategic questions shaping biopharma.
ClearView Healthcare Partners makes a strategic investment in Epistemic AI
A $4 million investment to advance biomedical AI and combine Epistemic AI's technology with ClearView's life-science expertise.
Read the announcementEpistemic AI unveils next-generation biomedical GPT technology
A generative AI system designed to give life-science professionals faster access to complex biomedical information.
Read the announcementEpistemic AI launches biomedical GPT at BIO
PharmaPhorum covers the launch of EpistemicGPT and its connection to a curated biomedical knowledge graph.
Read the coverageSomnus Scientific enhances competitive intelligence with Epistemic AI
Somnus Scientific selected the research intelligence platform to accelerate competitive intelligence and trend analysis.
Read the announcement